A clinical trial consisting of 156 patients demonstrated that the use of SGLT-2 inhibitors not only enhanced blood glucose control in individuals with NAFLD and T2DM but also significantly reduced visceral fat area and body weight [37]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.